NCT07444398RecruitingPhase 1
Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial
Source: ClinicalTrials.gov · Last updated 2 Mar 2026
Brief summary (registry, in English)
This study will compare the outcomes of Vericuguat and placebo in patient with decompensated heart failure . This study will carry out after approval from IERB. Seventy patients fulfilling the inclusion criteria will be enrolled from emergency department. Informed consent will be taken from attendants. A detailed history including name, age, gender, duration of heart failure, history of alcoholism, smoking, diabetes, hypertension, EF at baseline and NYHA class will be noted. Patients will be randomly divided in two groups by using lottery method. Outcomes will be assessed at in terms of hospitalization for heart failure, death from cardiovascular event and side effects.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- First submitted
- 26 Feb 2026
- Start date
- 1 Jan 2026
- Primary completion date
- 31 Mar 2026
- Lead sponsor
- Khawaja Danish Ali
- Diseases
- Heart failure
- NCT number
- NCT07444398
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 130
- From 1 Jan 2026 to the primary completion date, 31 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- concurrent or anticipated use of long-acting nitrates, soluble guanylate cyclase stimulators, or phosphodiesterase type 5 inhibitors
Other
- Patients with blood pressure \<100 mmHg;
- use of intravenous inotropes or implantable left ventricular assist devices (on medical record)
Who the study is looking for
- Patients diagnosed with decompensated heart failure (patients with left ventricular ejection fraction ≤45% presenting with NYHA functional class III-IV symptoms or worsening class II symptoms. Along with elevated natriuretic peptide levels defined as NT-proBNP \>1000 pg/mL in patients with sinus rhythm and \>1600 pg/mL in patients with atrial fibrillation in the absence of alternative causes of biomarker elevation)
Age in the registry: 25 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Armed Forces Institute of Cardiology. Pakistan Coordinator of this site? Confirm its status | Rawalpindi | Pakistan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.